Taysha Gene Therapies, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+171.3% +$3M
$5M
R&D↑+62.8% +$10M
$25M
D&A↓-1.6% -$5K
$299K
Operating Income↓-31.4% -$8M
$-34M
EBITDA↓-1.6% -$5K
$299K
Interest Expense↓-45.5% -$10K
$12K
Interest Income↑+68.8% +$1M
$3M
Tax Provision
$0
Net Income↓-28.2% -$7M
$-33M
Operating Margin↑+568.3pts
-1347.1%
Net Margin↑+528.4pts
-1353.6%
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-0.0pts
-0.0%
Operating Lease Cost↑+15.2% +$102K
$772K
Revenue YoY Variation↑+215.2pts
171.3%
Income YoY Variation↑+28.0pts
-31.4%
Revenue QoQ Variation↓-160.8pts
-100.0%
Income QoQ Variation↓-5.6pts
-27.2%